Effects of Psilocybin on Mouse Brain Microstructure

References

1. 1.↵
   1. Khan AJ,
   2. Bradley E,
   3. O’Donovan A, et al

   . Psilocybin for trauma-related disorders. Curr Top Behav Neurosci 2022;56:319–32 doi:10.1007/7854_2022_366 pmid:35711024

   CrossRefPubMed
2. 2.↵
   1. Moreno FA,
   2. Wiegand CB,
   3. Taitano EK, et al

   . Safety, tolerability, and efficacy of psilocybin in 9 patients with obsessive-compulsive disorder. J Clin Psychiatry 2006;67:1735–40

   CrossRefPubMedWeb of Science
3. 3.↵
   1. Bogenschutz MP,
   2. Forcehimes AA,
   3. Pommy JA, et al

   . Psilocybin-assisted treatment for alcohol dependence: a proof-of-concept study. J Psychopharmacol 2015;29:289–99 doi:10.1177/0269881114565144

   CrossRefPubMed
4. 4.↵
   1. Carhart-Harris RL,
   2. Bolstridge M,
   3. Rucker J, et al

   . Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study. Lancet Psychiatry 2016;3:619–27 doi:10.1016/S2215-0366(16)30065-7 pmid:27210031

   CrossRefPubMed
5. 5.↵
   1. Davis AK,
   2. Barrett FS,
   3. May DG, et al

   . Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial. JAMA Psychiatry 2021;78:481–89 doi:10.1001/jamapsychiatry.2020.3285 pmid:33146667

   CrossRefPubMed
6. 6.↵
   1. Raison CL,
   2. Sanacora G,
   3. Woolley J, et al

   . Single-dose psilocybin treatment for major depressive disorder. JAMA 2023;330:843 doi:10.1001/jama.2023.14530

   CrossRefPubMed
7. 7.↵
   1. van Amsterdam J,
   2. van den Brink W

   . The therapeutic potential of psilocybin: a systematic review. Expert Opin Drug Saf 2022;21:833–40 doi:10.1080/14740338.2022.2047929 pmid:35225143

   CrossRefPubMed
8. 8.↵
   1. Goel DB,
   2. Zilate S

   . Potential therapeutic effects of psilocybin: a systematic review. Cureus 2022;14:e30214 doi:10.7759/cureus.30214 pmid:36381758

   CrossRefPubMed
9. 9.↵
   1. Goodwin GM,
   2. Aaronson ST,
   3. Alvarez O, et al

   . Single-dose psilocybin for a treatment-resistant episode of major depression. N Engl J Med 2022;387:1637–48 doi:10.1056/NEJMoa2206443

   CrossRefPubMed
10. 10.↵
    1. Shao LX,
    2. Liao C,
    3. Gregg I, et al

    . Psilocybin induces rapid and persistent growth of dendritic spines in frontal cortex in vivo. Neuron 2021;109:2535–44 doi:10.1016/j.neuron.2021.06.008 pmid:34228959

    CrossRefPubMed
11. 11.↵
    1. de la Fuente Revenga M,
    2. Zhu B,
    3. Guevara CA, et al

    . Prolonged epigenomic and synaptic plasticity alterations following single exposure to a psychedelic in mice. Cell Rep 2021;37:109836 doi:10.1016/j.celrep.2021.109836 pmid:34686347

    CrossRefPubMed
12. 12.↵
    1. Davoudian PA,
    2. Shao LX,
    3. Kwan AC

    . Shared and distinct brain regions targeted for immediate early gene expression by ketamine and psilocybin. ACS Chem Neurosci 2023;14:468–80 doi:10.1021/acschemneuro.2c00637 pmid:36630309

    CrossRefPubMed
13. 13.↵
    1. Martin DA,
    2. Nichols CD

    . Psychedelics recruit multiple cellular types and produce complex transcriptional responses within the brain. EBioMedicine 2016;11:262–77 doi:10.1016/j.ebiom.2016.08.049 pmid:27649637

    CrossRefPubMed
14. 14.↵
    1. Hesselgrave N,
    2. Troppoli TA,
    3. Wulff AB, et al

    . Harnessing psilocybin: antidepressant-like behavioral and synaptic actions of psilocybin are independent of 5-HT2R activation in mice. Proc Natl Acad Sci U S A 2021;118:e2022489118 doi:10.1073/pnas.2022489118

    Abstract/FREE Full Text
15. 15.↵
    1. Preller KH,
    2. Duerler P,
    3. Burt JB, et al

    . Psilocybin induces time-dependent changes in global functional connectivity. Biol Psychiatry 2020;88:197–207 doi:10.1016/j.biopsych.2019.12.027 pmid:32111343

    CrossRefPubMed
16. 16.↵
    1. Grimm O,
    2. Kraehenmann R,
    3. Preller KH, et al

    . Psilocybin modulates functional connectivity of the amygdala during emotional face discrimination. Eur Neuropsychopharmacol 2018;28:691–700 doi:10.1016/j.euroneuro.2018.03.016

    CrossRefPubMed
17. 17.↵
    1. Carhart-Harris RL,
    2. Leech R,
    3. Hellyer PJ, et al

    . The entropic brain: a theory of conscious states informed by neuroimaging research with psychedelic drugs. Front Hum Neurosci 2014;8:20 doi:10.3389/fnhum.2014.00020 pmid:24550805

    CrossRefPubMed
18. 18.↵
    1. Barrett FS,
    2. Doss MK,
    3. Sepeda ND, et al

    . Emotions and brain function are altered up to one month after a single high dose of psilocybin. Sci Rep 2020;10:2214 doi:10.1038/s41598-020-59282-y pmid:32042038

    CrossRefPubMed
19. 19.↵
    1. McCulloch DEW,
    2. Madsen MK,
    3. Stenbæk DS, et al

    . Lasting effects of a single psilocybin dose on resting-state functional connectivity in healthy individuals. J Psychopharmacol 2022;36:74–84 doi:10.1177/02698811211026454

    CrossRefPubMed
20. 20.↵
    1. Daws RE,
    2. Timmermann C,
    3. Giribaldi B, et al

    . Increased global integration in the brain after psilocybin therapy for depression. Nat Med 2022;28:844–51 doi:10.1038/s41591-022-01744-z pmid:35411074

    CrossRefPubMed
21. 21.↵
    1. Tagliazucchi E,
    2. Carhart-Harris R,
    3. Leech R, et al

    . Enhanced repertoire of brain dynamical states during the psychedelic experience. Hum Brain Mapp 2014;35:5442–56 doi:10.1002/hbm.22562 pmid:24989126

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Frautschi PC,
    2. Singh AP,
    3. Stowe NA, et al

    . Multimodal neuroimaging of the effect of serotonergic psychedelics on the brain. AJNR Am J Neuroradiol 2024;45:833–40 doi:10.3174/ajnr.A8118 pmid:38360790

    Abstract/FREE Full Text
23. 23.↵
    1. Yi SY,
    2. Barnett BR,
    3. Yu JPJ

    . Preclinical neuroimaging of gene-environment interactions in psychiatric disease. Br J Radiol 2019;92:20180885

    CrossRefPubMed
24. 24.↵
    1. Zhang H,
    2. Schneider T,
    3. Wheeler-Kingshott CA, et al

    . NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 2012;61:1000–16 doi:10.1016/j.neuroimage.2012.03.072 pmid:22484410

    CrossRefPubMed
25. 25.↵
    1. Faillace LA,
    2. Vourlekis A,
    3. Szara S

    . Clinical evaluation of some hallucinogenic tryptamine derivatives. J Nerv Ment Dis 1967;145:306–13

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Blair JB,
    2. Kurrasch-Orbaugh D,
    3. Marona-Lewicka D, et al

    . Effect of ring fluorination on the pharmacology of hallucinogenic tryptamines. J Med Chem 2000;43:4701–10 doi:10.1021/jm000339w pmid:11101361

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Ly C,
    2. Greb AC,
    3. Cameron LP, et al

    . psychedelics promote structural and functional neural plasticity. Cell Rep 2018;23:3170–82 doi:10.1016/j.celrep.2018.05.022 pmid:29898390

    CrossRefPubMed
28. 28.↵
    1. Gattuso JJ,
    2. Wilson C,
    3. Hannan AJ, et al

    . Psilocybin as a lead candidate molecule in preclinical therapeutic studies of psychiatric disorders: a systematic review. J Neurochem 2024;168:1687–720 doi:10.1111/jnc.16017 pmid:38019032

    CrossRefPubMed
29. 29.↵
    1. Holmes HE,
    2. Powell NM,
    3. Ma D, et al

    . Comparison of in vivo and ex vivo MRI for the detection of structural abnormalities in a mouse model of tauopathy. Front Neuroinform 2017;11:20 doi:10.3389/fninf.2017.00020 pmid:28408879

    CrossRefPubMed
30. 30.↵
    1. Lerch JP,
    2. Gazdzinski L,
    3. Germann J, et al

    . Wanted dead or alive? The tradeoff between in-vivo versus ex-vivo MR brain imaging in the mouse. Front Neuroinform 2012;6:6 doi:10.3389/fninf.2012.00006 pmid:22470335

    CrossRefPubMed
31. 31.↵
    1. Paxinos G,
    2. Franklin KBJ

    . The Mouse Brain in Stereotaxic Coordinates: Hard Cover Edition. 2nd ed. Academic Press; 2001.
32. 32.↵
    1. Zhang Y,
    2. Zhang Y,
    3. Ai H, et al

    . Microstructural deficits of the thalamus in major depressive disorder. Brain Commun 2022;4:fcac236 doi:10.1093/braincomms/fcac236 pmid:36196087

    CrossRefPubMed
33. 33.↵
    1. Kumar P,
    2. Goer F,
    3. Murray L, et al

    . Impaired reward prediction error encoding and striatal-midbrain connectivity in depression. Neuropsychopharmacology 2018;43:1581–88 doi:10.1038/s41386-018-0032-x pmid:29540863

    CrossRefPubMed
34. 34.↵
    1. Nestler EJ,
    2. Barrot M,
    3. DiLeone RJ, et al

    . Neurobiology of depression. Neuron 2002;34:13–25 doi:10.1016/s0896-6273(02)00653-0 pmid:11931738

    CrossRefPubMedWeb of Science
35. 35.↵
    1. Andrade C

    . Multiple testing and protection against a type 1 (false positive) error using the Bonferroni and Hochberg corrections. Indian J Psychol Med 2019;41:99–100 doi:10.4103/IJPSYM.IJPSYM_499_18 pmid:30783320

    CrossRefPubMed
36. 36.↵
    1. Nutt D,
    2. Erritzoe D,
    3. Carhart-Harris R

    . Psychedelic psychiatry’s brave new world. Cell 2020;181:24–28 doi:10.1016/j.cell.2020.03.020 pmid:32243793

    CrossRefPubMed
37. 37.↵
    1. Carhart-Harris RL,
    2. Friston KJ

    . REBUS and the anarchic brain: toward a unified model of the brain action of psychedelics. Pharmacol Rev 2019;71:316–44 doi:10.1124/pr.118.017160 pmid:31221820

    Abstract/FREE Full Text
38. 38.↵
    1. Barrett FS,
    2. Krimmel SR,
    3. Griffiths R, et al

    . Psilocybin acutely alters the functional connectivity of the claustrum with brain networks that support perception, memory, and attention. Neuroimage 2020;218:116980 doi:10.1016/j.neuroimage.2020.116980 pmid:32454209

    CrossRefPubMed
39. 39.↵
    1. Carhart-Harris RL,
    2. Erritzoe D,
    3. Williams T, et al

    . Neural correlates of the psychedelic state as determined by fMRI studies with psilocybin. Proc Natl Acad Sci U S A 2012;109:2138–43 doi:10.1073/pnas.1119598109 pmid:22308440

    Abstract/FREE Full Text
40. 40.↵
    1. Gaddis A,
    2. Lidstone DE,
    3. Nebel MB, et al

    . Psilocybin induces spatially constrained alterations in thalamic functional organizaton and connectivity. Neuroimage 2022;260:119434 doi:10.1016/j.neuroimage.2022.119434 pmid:35792293

    CrossRefPubMed
41. 41.↵
    1. Siegel JS,
    2. Subramanian S,
    3. Perry D, et al

    . Psilocybin desynchronizes the human brain. Nature 2024;632:131–38 doi:10.1038/s41586-024-07624-5 pmid:39020167

    CrossRefPubMed
42. 42.↵
    1. Van De Werd HJJM,
    2. Uylings HBM

    . Comparison of (stereotactic) parcellations in mouse prefrontal cortex. Brain Struct Funct 2014;219:433–59 doi:10.1007/s00429-013-0630-7 pmid:24072162

    CrossRefPubMed
43. 43.↵
    1. Pearson J,
    2. Chiou R,
    3. Rogers S, et al

    . Sensory dynamics of visual hallucinations in the normal population. Elife 2016;5:e17072 doi:10.7554/eLife.17072

    CrossRefPubMed
44. 44.↵
    1. Bhome R,
    2. Thomas GEC,
    3. Zarkali A, et al

    . Structural and functional imaging correlates of visual hallucinations in Parkinson’s disease. Curr Neurol Neurosci Rep 2023;23:287–99 doi:10.1007/s11910-023-01267-1 pmid:37126201

    CrossRefPubMed
45. 45.↵
    1. Copa D,
    2. Erritzoe D,
    3. Giribaldi B, et al

    . Predicting the outcome of psilocybin treatment for depression from baseline fMRI functional connectivity. J Affect Disord 2024;353:60–69 doi:10.1016/j.jad.2024.02.089 pmid:38423367

    CrossRefPubMed
46. 46.↵
    1. Gattuso JJ,
    2. Perkins D,
    3. Ruffell S, et al

    . Default mode network modulation by psychedelics: a systematic review. Int J Neuropsychopharmacol 2023;26:155–88 doi:10.1093/ijnp/pyac074

    CrossRef
47. 47.↵
    1. Lyons T,
    2. Spriggs M,
    3. Kerkelä L, et al

    . Human brain changes after first psilocybin use. bioRxiv doi:10.1101/2024.10.11.617955. Accessed .

    Abstract/FREE Full Text
48. 48.↵
    1. Jaster AM,
    2. Younkin J,
    3. Cuddy T, et al

    . Differences across sexes on head-twitch behavior and 5-HT2A receptor signaling in C57BL/6J mice. Neurosci Lett 2022;788:136836 doi:10.1016/j.neulet.2022.136836 pmid:35963476

    CrossRefPubMed